Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Amortization - Intangibles (2017 - 2025)

Adma Biologics' Amortization - Intangibles history spans 9 years, with the latest figure at $51000.0 for Q4 2025.

  • For Q4 2025, Amortization - Intangibles rose 104.0% year-over-year to $51000.0; the TTM value through Dec 2025 reached $146000.0, down 62.37%, while the annual FY2025 figure was $144000.0, 62.89% down from the prior year.
  • Amortization - Intangibles reached $51000.0 in Q4 2025 per ADMA's latest filing, up from $38000.0 in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $224000.0 in Q4 2023 to a low of $25000.0 in Q4 2024.
  • Average Amortization - Intangibles over 5 years is $141558.1, with a median of $178919.0 recorded in 2022.
  • Peak YoY movement for Amortization - Intangibles: plummeted 88.84% in 2024, then skyrocketed 104.0% in 2025.
  • A 5-year view of Amortization - Intangibles shows it stood at $200000.0 in 2021, then decreased by 10.76% to $178486.0 in 2022, then grew by 25.5% to $224000.0 in 2023, then tumbled by 88.84% to $25000.0 in 2024, then surged by 104.0% to $51000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Amortization - Intangibles are $51000.0 (Q4 2025), $38000.0 (Q3 2025), and $32000.0 (Q2 2025).